Skip to main content
. 2016 Nov 28;24(4):914–922. doi: 10.1245/s10434-016-5686-1

Fig. 1.

Fig. 1

Overall survival and progression-free survival in the 511 patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. OS overall survival, PFS progression-free survival